LAVA Therapeutics B.V. is a biotechnology company. It focuses on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy. LAVA Therapeutics B.V. is based in UTRECHT, The Netherlands.
| Revenue (Most Recent Fiscal Year) | $11.98M |
| Net Income (Most Recent Fiscal Year) | $-25.11M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -545.07% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -86.38% |
| Return on Assets (Trailing 12 Months) | -34.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.73 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.73 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.94 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.04 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 26.31M |
| Free Float | 23.81M |
| Market Capitalization | $40.25M |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | 0.50 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |